Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y4J8
UPID:
DTNA_HUMAN
Alternative names:
Alpha-dystrobrevin; Dystrophin-related protein 3
Alternative UPACC:
Q9Y4J8; A8K541; A8MSZ0; A8MUY4; B4DGS6; B4DIR0; B4DIU8; M0QYX6; M0R397; O15332; O15333; O75697; Q13197; Q13198; Q13199; Q13498; Q13499; Q13500; Q59GK7; Q9BS59
Background:
Dystrobrevin alpha, also known as Alpha-dystrobrevin or Dystrophin-related protein 3, plays a crucial role in the formation and stability of synapses, alongside clustering of nicotinic acetylcholine receptors. Its unique functions contribute significantly to the integrity of muscular and neuronal systems.
Therapeutic significance:
The protein's involvement in Left ventricular non-compaction 1, a cardiomyopathy characterized by a hypertrophic left ventricle and poor systolic function, highlights its potential as a target for therapeutic intervention. Understanding the role of Dystrobrevin alpha could open doors to potential therapeutic strategies for this and possibly other related cardiac conditions.